Company / Free Cash Flow
Vistagen Therapeutics, Inc. Free Cash Flow History
FY2017-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$45.3M
FY2023
5-year range
-$45.3M / -$4.8M
FY2019-FY2023
Trend
-266.5%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow changed -266% YoY in FY2023, a notable deviation from the 4-year average annual change of -103%.
Based on SEC 10-K filings.
-$45M in FY2023.
Declined from -$16M to -$45M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, free cash flow decreased 266.5% year-over-year.
- Peak free cash flow was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | -$45.3M | -266.5% |
| FY2022 | -$12.3M | +21.6% |
| FY2021 | -$15.8M | -110.1% |
| FY2018 | -$7.5M | -55.2% |
| FY2017 | -$4.8M | - |
| FY2014 | - | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026